CREATINE IN PARTICIPANTS WITH TREATED PARKINSON'S DISEASE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项试验的主要研究目的是比较肌酸组和安慰剂组在多巴胺能治疗和最佳医疗护理的背景下，通过施瓦布和英格兰的ADL(PD功能)、PDQ-39(QOL)、活动能力(5个UPDRS问题的总和：跌倒、冻结、行走、步态、姿势稳定性)、符号数字形式(认知障碍)和修正的Rankin值(全球功能)来衡量的主要结果。研究假设是，根据由上述指标组成的全球统计测试的评估，接受肌酸治疗的小组在5年内表现出的疾病进展将比服用安慰剂的小组更少。第二个目标是利用基线和5年随访的数据，比较肌酸肌酸组和安慰剂组在有效性、安全性和耐受性方面的额外测量。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary study aim of this trial is to compare the primary outcome as measured by the Schwab and England ADl (PD function), PDQ-39 (QOL), ambulatory capacity (sum of 5 UPDRS questions: falling, freezing, walking, gait, postural stablity), Symbol Digit Modalities (cognative impairment), and Modified Rankin Value (global functioning) in the creatine group versus the placebo group against a background of dopaminergic therapy and best medical care. The research hypothesis is that the group being treated with creatine will show less disease progression by 5 years than the group on placebo as evalutated by a Global Statistical Test comprised of the above measures. Secondard aims are to compare the creaine and placebo groups on additaional measure of efficacy, safety, and tolerability using data between baseline and 5 years follow up.